Trials / Completed
CompletedNCT01305252
A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
CombinatiON Up-FRON t Therapy for PAH - A Phase 4, Randomized, Multicenter Study of Inhaled Treprostinil in Treatment naïve Pulmonary Arterial Hypertension Patients Starting on Tadalafil
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
The Study Hypothesis: Aggressive, upfront, dual therapy for treatment-naïve NYHA I/II/III PAH is superior to a traditional "step-up" approach. The study will evaluate: 1. Impact of dual, upfront, therapy on cardiovascular parameters in PAH as gauged by cardiac magnetic resonance imaging (cMRI) at 24 weeks and event free survival at outcome at 48 weeks. 2. Value of novel biomarkers (NT-pro BNP, Mts1/S100A4, and insulin resistance) and cutting-edge imaging technologies (cardiac MRI) as newer endpoints for clinical trials in PAH. 3. Utility of longer clinical trial design with the use of combined clinical events as time to clinical worsening surrogate
Detailed description
This is a 48 week interventional study evaluating the effect of Dual therapy ( Treprostinil inhalations and Tadalafil) versus Mono therapy (Tadalafil). The impact of the therapy on cardiovascular parameters in PAH measured at 24 weeks and event free survival outcome at 48 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | treprostinil inhalations | Treprostinil inhalation QID starting at 3 breaths per inhalation \& gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil. |
| DRUG | tadalafil | tadalafil 20mg QD PO increasing to 40mg QD as tolerated |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2011-02-28
- Last updated
- 2017-06-02
- Results posted
- 2017-06-02
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01305252. Inclusion in this directory is not an endorsement.